Quoin Pharmaceuticals Ltd.
QNRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001671502
In the last 90 days, Quoin Pharmaceuticals Ltd. insiders filed 4 open-market purchases and 0 sales; 19 institutions reported holding it in 13F filings for Q2 2026, worth $6.29M in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in Quoin Pharmaceuticals Ltd. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 6
- −4 vs. Q1 2025
- Shares held
- 2.54K
- −399.1K (−99.4%) vs. Q1 2025
- Total value
- $23.4K
- −$66.8K (−74.1%) vs. Q1 2025
- New holders
- 1
- 0 more added
- Sold out
- 5
- 5 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting QNRX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 19 | $6.29M |
| Q1 2026 | 21 | $7.82M |
| Q4 2025 | 18 | $12.2M |
| Q3 2025 | 4 | $10.7K |
| Q2 2025 | 6 | $23.4K |
| Q1 2025 | 10 | $90.2K |
| Q4 2024 | 14 | $1.01M |
| Q3 2024 | 7 | $82.2K |
| Q2 2024 | 10 | $127.7K |
| Q1 2024 | 8 | $183.2K |
| Q4 2023 | 3 | $105.6K |
| Q3 2023 | 3 | $7.21K |
| Q2 2023 | 2 | $24.0K |
| Q1 2023 | 4 | $81.1K |
| Q4 2022 | 4 | $52.0K |
| Q3 2022 | 7 | $272.0K |
| Q2 2022 | 8 | $321.0K |
| Q1 2022 | 6 | $419.0K |
| Q4 2021 | 7 | $383.0K |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Quoin Pharmaceuticals Ltd.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Rhumbline Advisers | 1,242 | $11.4K | 0.00% | −40,499−97.0% | Reduced |
| Raymond James Financial Inc | 717 | $6.62K | 0.00% | −24,402−97.1% | Reduced |
| GAMMA Investing LLC | 240 | $2.21K | 0.00% | +240 | New |
| Morgan Stanley | 206 | $1.90K | 0.00% | −250−54.8% | Reduced |
| UBS Group AG | 130 | $1.20K | 0.00% | −219,165−99.9% | Reduced |
| SBI Securities Co., Ltd. | 2 | $18 | 0.00% | −106−98.1% | Reduced |
| Apollon Wealth Management, LLC | 0 | $0 | 0.00% | −80,025−100.0% | Sold out |
| Lido Advisors, LLC | 0 | $0 | 0.00% | −23,515−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −11,210−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −144−100.0% | Sold out |
| Raiffeisen Bank International AG | 0 | $0 | 0.00% | −17−100.0% | Sold out |